BD company Wikipedia

Designed and validated for use with cell suspensions, whole blood and tissue pieces. BD Horizon RealViolet™ 544 Reagents offer limited spillover, robust intracellular performance and lot-to-lot consistency.

BD FACSDiscover™ S8 Cell Sorter

• The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America.
• The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson.
• BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death.
• The BD Rhapsody™ single-cell platform has been a key tool for the publication of our clinical research.
• The company’s line of plastic conical screwtop test tubes, known as ‘Falcon tubes’, is popular and the term is sometimes used as a generic term for such tubes.

Embecta Corporation is a standalone public company focused on diabetes care. Explore a variety of tools for your multicolor flow cytometry, from panel design to selection tools—an array of aids to support your research. In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years. Food and Drug Administration and worldwide health agencies to coordinate recall activities.

The company’s line of plastic conical screwtop test tubes, known as ‘Falcon tubes’, is popular and the term is sometimes used as a generic term for such tubes. In certain places, BD Medical also offers consulting and analytics related chickenroadonline-bd.com services. In July 2021, BD announced it would acquire surgical scaffold maker Tepha, after having acquired Velano Vascular earlier the same month.

Advancing the world of health™

The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. In 2024, BD announced it would acquire Edwards Lifesciences’ critical care unit for $4.2 billion. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. Houses many of our pre-designed multicolor flow cytometry panels.

This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products. The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. In April 2017, Becton, Dickinson and Company announced it would acquire C. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. The lawsuit touched off a series of legal conflicts between the companies.

The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. Use a variety of training courses for instruments and applications to take full advantage of the capabilities of BD products. Explore our webinar series spanning a broad range of topics and in-depth reviews by senior scientists, professionals and clinicians.

A comprehensive suite of trusted products, integrated solutions, useful tools and a wealth of information to advance your flow cytometry applications. BD announced that it notified customers about the recall by letter and has been working with the U.S. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.

Search or filter to find and learn more about the panels. These subtle changes would not have been discovered without the use of a powerful, highly sensitive technique such as the BD Rhapsody™ single-cell platform. The BD Rhapsody™ single-cell platform has been a key tool for the publication of our clinical research. Backed by cutting-edge technology and more than 50 years of flow cytometry expertise